10-Q: SELLAS Reports Q2 2025 Results, Advances Cancer Therapies

SELLAS Life Sciences Group reports reduced net loss and operating expenses in Q2 2025, driven by progress in its oncology pipeline and recent financing activities, but faces ongoing liquidity challenges.

Summary

• Net loss for the six months ended June 30, 2025, decreased to $12.4 million from $17.0 million in the prior year period.
• Research and development expenses decreased by $3.2 million to $7.1 million for the six months ended June 30, 2025, primarily due to the completion of enrollment in the REGAL study.
• General and administrative expenses decreased by $1.1 million to $5.9 million for the six months ended June 30, 2025, mainly due to a one-time severance charge in the prior period.
• Cash and cash equivalents increased to $25.3 million as of June 30, 2025, from $13.9 million at December 31, 2024.
• The company consummated a registered direct offering on January 29, 2025, generating approximately $23.1 million in net proceeds.
• An additional $5.0 million was raised from warrant exercises during the six months ended June 30, 2025, with a further $3.7 million received post-quarter end.
• The Phase 3 REGAL study for GPS in AML continues without modification following positive recommendations from the Independent Data Monitoring Committee (IDMC) in January and August 2025.
• The Phase 2 trial of SLS009 in relapsed/refractory AML met all primary endpoints in July 2025, showing an overall response rate (ORR) of 33% across all cohorts and a median overall survival (mOS) of 8.9 months in AML MR patients, surpassing historical benchmarks.
• The FDA recommended advancing SLS009 into a first-line AML patient study, expected to begin enrollment by Q1 2026.
• The company has an accumulated deficit of $260.5 million as of June 30, 2025, and expects current cash to be insufficient for planned operations for at least the next twelve months, raising substantial doubt about its going concern ability.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to strong clinical trial results for SLS009 and reduced operating losses, indicating progress in the pipeline and financial efficiency. However, the significant going concern warning and the ongoing need for substantial additional financing temper the overall positive outlook, reflecting considerable financial risk.

Positives

• Net loss significantly decreased to $12.4 million for the six months ended June 30, 2025, compared to $17.0 million for the same period in 2024.
• Operating expenses decreased by $4.3 million, from $17.3 million in 2024 to $12.9 million in 2025, reflecting improved cost management.
• Cash and cash equivalents increased to $25.3 million as of June 30, 2025, from $13.9 million at December 31, 2024, strengthening the liquidity position.
• The Phase 3 REGAL study for GPS received positive recommendations from the IDMC in January and August 2025 to continue without modifications, indicating favorable safety and efficacy trends.
• The Phase 2 trial of SLS009 in relapsed/refractory AML met all primary endpoints, demonstrating an overall response rate of 33% and a median overall survival of 8.9 months in AML MR patients, significantly exceeding the historical benchmark of ~2.4 months.
• The FDA recommended advancing SLS009 into a first-line AML patient study, signaling strong regulatory confidence and potential for broader market impact.
• SLS009 was well-tolerated in trials with no new safety signals or dose-limiting toxicities observed.
• GPS and SLS009 have received multiple Orphan Drug and Fast Track designations from the FDA and EMA, and Rare Pediatric Disease designations from the FDA, which can expedite development and provide market exclusivity benefits.
• Preclinical studies identified ASXL1 mutation as a key predictor of SLS009 response in solid cancers, potentially enabling targeted therapy.
• SLS009 demonstrated significant efficacy in pediatric acute lymphoblastic leukemia (ALL) patient-derived xenografts, tripling median survival and showing complete responses in some models.

Negatives

• The company incurred a net loss of $12.4 million for the six months ended June 30, 2025, and has an accumulated deficit of $260.5 million.
• Used $16.4 million of cash in operations during the six months ended June 30, 2025.
• Current cash and cash equivalents are not sufficient to fund planned operations for at least the next twelve months, raising substantial doubt about the company's ability to continue as a going concern.
• The company currently has no commitments to obtain additional funding, relying on future public/private placements or collaborations.
• A binding arbitration proceeding against 3D Medicines Inc. is ongoing regarding the trigger and payment of $13.0 million in milestone payments and 3D Medicines' failure to use commercially reasonable best efforts to develop GPS in the 3DMed Territory.

Risks

• The company has incurred recurring losses and negative cash flows from operations since inception, with an accumulated deficit of $260.5 million as of June 30, 2025.
• Current cash and cash equivalents are not sufficient to fund planned operations for at least the next twelve months, indicating substantial doubt about the company's ability to continue as a going concern.
• The company will require substantial additional financing to commercially develop any current or future product candidates, with no assurance that future funding efforts will be successful.
• The transition to profitability is dependent upon the successful development, approval, and commercialization of product candidates and achieving adequate revenues.
• The timing of the final analysis for the REGAL study is event-driven and difficult to predict with certainty, potentially occurring at a different time than currently expected.
• The arbitration proceeding against 3D Medicines Inc. involves uncertainties regarding its outcome and the timing of any milestone payments or damages.
• The successful development of product candidates is highly uncertain, with significant variability in the duration and cost of clinical trials due to factors like patient enrollment, follow-up duration, and manufacturing expenses.
• The company may obtain unexpected results from clinical trials or may elect to discontinue, delay, or modify trials, which could significantly impact costs and timing.
• Regulatory authorities may require additional clinical trials beyond current anticipation, or significant delays in enrollment could lead to substantial additional financial resources and time.

Future Outlook

The company anticipates continued operating losses and negative cash flows for the next few years, requiring substantial additional financing to support planned activities through profitability. The final analysis for the GPS REGAL study is expected once 80 events (deaths) are reached, anticipated this year. For SLS009, the FDA has recommended proceeding into a randomized 80-patient trial for newly diagnosed, first-line AML patients, with enrollment expected to begin by the first quarter of 2026. The company is evaluating the impact of the recently enacted 'One Big Beautiful Bill Act of 2025' on its financial statements.

Management Comments

• Management continues to evaluate different strategies to obtain the required funding for future operations, including public and private placements of equity and/or debt securities, as well as payments from potential strategic research and development collaborations or licensing and/or marketing arrangements with pharmaceutical companies.
• Management continues to pursue discussions with global and regional pharmaceutical companies for licensing and/or co-development rights to product candidates.

Industry Context

The biopharmaceutical industry, particularly oncology, is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. SELLAS's focus on immunotherapeutic agents like GPS (targeting WT1 protein) and highly selective CDK9 inhibitors like SLS009 aligns with current trends in precision oncology and combination therapies aimed at improving patient outcomes and reducing toxicity. The success of SLS009 in relapsed/refractory AML and its potential for first-line therapy, along with its efficacy in pediatric ALL models, positions it favorably in a high-need area. The ongoing arbitration with 3D Medicines highlights the complexities of international licensing agreements in the pharmaceutical sector.

Comparison to Industry Standards

• SLS009's median overall survival (mOS) of 8.9 months in AML MR patients and 8.8 months in patients r/r to venetoclax-based regimens at a 30 mg BIW dose level significantly surpasses the historical benchmark of approximately 2.4 months for similar patient populations, indicating strong efficacy relative to current standards.
• The high selectivity of SLS009 is noted to have the potential to reduce toxicity compared to older CDK9 inhibitors and other next-generation CDK9 inhibitors currently in clinical development, suggesting a favorable safety profile compared to competitors like those developing less selective CDK9 inhibitors.
• The observed high rate of responses in patients with myelodysplasia-related molecular mutations (AML MR) and ASXL1 gene mutations for SLS009 is a key differentiator, as ASXL1 mutations are typically associated with poor prognosis and reduced response to current treatment options in myeloid diseases.
• In pediatric acute lymphoblastic leukemia (ALL) patient-derived xenografts, SLS009 demonstrated a tripling of median survival and delayed progression in 93% of models, with complete responses in two models, which is a highly promising result compared to typical outcomes in such aggressive pediatric cancers.

Corporate Governance

Legal Proceedings

• A binding arbitration proceeding against 3D Medicines Inc. commenced on December 20, 2023, administered by the Hong Kong International Arbitration Centre. The arbitration involves the trigger and payment of relevant milestone payments due to the company under the 3D Medicines Agreement, as well as 3D Medicines' alleged failure to use commercially reasonable best efforts to develop GPS in the 3DMed Territory. The company believes its claims are meritorious.

Stakeholder Impact

• **Shareholders**: Positive clinical trial results for SLS009 and reduced net loss could increase investor confidence, but the going concern warning and need for future capital raises introduce significant dilution risk and financial uncertainty.
• **Employees**: The approval of the Amended and Restated 2021 Employee Stock Purchase Plan provides expanded opportunities for employees to purchase company stock, potentially enhancing morale and retention.
• **Customers (Future Patients)**: Positive clinical data for SLS009 in AML and ALL, along with FDA guidance for a first-line AML trial, indicates potential for new, more effective treatment options for cancer patients.
• **Creditors**: The going concern warning and reliance on future financing may raise concerns for current and potential creditors regarding the company's ability to meet its long-term obligations.
• **Licensing Partners (GenFleet)**: The successful Phase 2 results and FDA guidance for SLS009 strengthen the value of the licensing agreement with GenFleet, potentially leading to future milestone payments.
• **Licensing Partners (3D Medicines)**: The ongoing arbitration proceeding creates uncertainty and potential financial implications for both parties, impacting the existing licensing agreement.

Next Steps

• Conduct the final analysis of the REGAL study for GPS once 80 events (deaths) are reached, anticipated this year.
• Prepare for and begin enrollment in a randomized 80-patient trial for SLS009 in newly diagnosed, first-line AML patients by the first quarter of 2026.
• Continue to evaluate different strategies to obtain required funding for future operations, including public and private placements of equity and/or debt securities, and strategic collaborations.
• Continue the binding arbitration proceeding against 3D Medicines Inc. to resolve disputes regarding milestone payments and development efforts.

Key Dates

Recommendation

While the clinical trial results for SLS009 are highly promising, particularly the strong efficacy data in r/r AML and the FDA's recommendation for a first-line trial, the company faces significant financial challenges. The explicit 'going concern' warning, substantial accumulated deficit, and the stated need for 'substantial additional financing' without current commitments present considerable liquidity risk. The positive clinical developments are balanced by the high financial uncertainty and potential for significant dilution from future capital raises. A 'hold' recommendation acknowledges the therapeutic potential while advising caution due to the precarious financial position.

Keywords

Oncology, Biopharmaceutical, Cancer Immunotherapy, AML, Acute Myeloid Leukemia, CDK9 Inhibitor, SLS009, Galinpepimut-S, GPS, Clinical Trials, Phase 3, Phase 2a, FDA, Orphan Drug Designation, Fast Track Designation, Rare Pediatric Disease Designation, Liquidity, Going Concern, Warrants, Equity Financing, Arbitration, ASXL1 mutation, Pediatric ALL